Abstract
Background Osteoarthritis (OA) and rheumatoid arthritis (RA) are prevalent forms of arthritis. Early detection of OA and RA is challenging with existing methods, which can delay effective management. MicroRNAs are small molecules that have emerged as promising disease biomarkers with the potential to improve early detection and differentiation of arthritis subtypes. In this study we aimed to identify distinct circulating microRNAs in plasma from individuals with early OA and early RA, using an unbiased microRNA-sequencing approach.
Methods Plasma samples were collected from three study groups including: (a) early OA (N=20), individuals with knee OA symptoms and radiographic Kellgren-Lawrence grade 0 or 1; (b) early RA (N=12), treatment-naïve individuals with <6 months of RA symptoms in any joint; and (c) non-OA/RA (N=44), individuals with no history of arthritis. Of these, N=62 samples were subjected to microRNA-sequencing and analysis using a previously optimized pipeline. Exploratory analyses were followed by a stepwise filtering approach to shortlist both known (documented in miRBase v22.1) and novel (predicted using bioinformatics) microRNAs. Prioritized microRNAs were then validated via real-time qPCR (RT-qPCR) in N=14 independent samples.
Results Principal component analyses revealed clustering of early OA versus both early RA and non-OA/RA groups, but not between early RA and non-OA/RA. In early OA, n=170 differentially expressed (DE) microRNAs were identified compared to both early RA and non-OA/RA, while no significant differences were found between early RA and non-OA/RA. Of these DE microRNAs, stepwise filtering and RT-qPCR validation identified dysregulation of six known microRNAs between early OA and early RA. Of these six microRNAs, two were upregulated in early OA, including hsa-miR-16-5p and hsa-miR-29c-3p, and four were upregulated in early RA, including hsa-miR-744-5p, hsa-miR-382-5p, hsa-miR-3074-5p, and hsa-miR-11400. Additionally, one novel microRNA sequence was found to be enriched in early OA and four in early RA.
Conclusion We identified a total of six known and five novel circulating microRNAs that differ between early OA and early RA individuals. Validation of these microRNAs in independent cohorts is warranted to establish their biomarker potential for distinguishing individuals with early OA versus early RA.
Competing Interest Statement
Shabana Amanada Ali declares that she has filed a US Provisional Patent Application no. 63/033,463 titled Circulating MicroRNAs in Knee Osteoarthritis and Uses Thereof. All other authors declare no competing interests.
Funding Statement
Funding for this study was provided by competitive grants awarded to Shabana Amanda Ali from the Pfizer Global Medical Grants (#72538937) and the University of Toronto McLaughlin Centre Accelerator Grant (#MC-2022-06), and to Michelle Ormseth by the Merit award (#I01CX002356) from the US Department of Veterans Affairs and the Discovery award (#HT9425-23-1-0044) from the Department of Defense, Peer Reviewed Medical Research Program.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Review Board of Henry Ford Health gave ethical approval for this work (IRB #13995).
The Institutional Review Board of VA Tennessee Healthcare System gave ethical approval for this work (IRB #1643056 and IRB #1722175).
The Federalwide Assurance committee and Institutional Review Board of University of California gave ethical approval for Osteoarthritis Initiative (FWA approval # 00000068; IRB approval # 10-00532).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The microRNA-sequencing datasets generated during this study were deposited in the Gene Expression Omnibus database and will be released following peer-reviewed publication.
List of abbreviations
- ACPA
- Anti-citrullinated protein antibody
- BLASTN
- nucleotide Basic Local Alignment Search Tool
- BMI
- Body mass index
- CPM
- Counts per million
- CRP
- C-reactive protein
- DE
- Differentially expressed
- DMARDs
- Disease-modifying anti-rheumatic drugs
- FC
- Fold-change
- FDR
- False discovery rate
- KL
- Kellgren-Lawrence
- PCA
- Principal component analysis
- RA
- Rheumatoid arthritis
- RF
- Rheumatoid factor
- RT-qPCR
- Real time polymerase chain reaction
- OA
- Osteoarthritis
